Description

Eterna Peptides presents premium-grade Liraglutide lyophilized powder, an advanced synthetic acylated glucagon-like peptide-1 (GLP-1) receptor agonist. Developed with a 97% structural homology to native human GLP-1, Liraglutide features a critical C16 fatty acid (palmitoyl) chain addition that drastically reduces its susceptibility to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation. Available in both 10mg and 20mg vial configurations, this metabolic research compound serves as an elite investigative tool for tracking appetite suppression, glycemic control mechanisms, and cellular energy homeostasis.

### Available Research Configurations
* **Liraglutide 10mg Vial:** Standardized for mid-tier metabolic modeling, baseline insulin sensitivity assays, and short-duration longitudinal research.
* **Liraglutide 20mg Vial:** High-capacity presentation engineered for high-saturation exposure screens, intensive multi-subject protocols, and extended experimental timelines.

### Mechanism of Action
Liraglutide operates via targeted structural activation of the G-protein coupled GLP-1 receptor, driving key metabolic cascades:
* **Incretin Mimicry & Glucose Regulation:** It activates pancreatic beta-cells to stimulate glucose-dependent insulin secretion while concurrently suppressing atypical glucagon production from alpha-cells, helping stabilize baseline glycemic indices under metabolic stress modeling.
* **Gastric Emptying De-acceleration:** In laboratory models, Liraglutide is tracked for its capacity to slow gastric emptying velocity, extending the duration of mechanical nutrient transit to study central satiety signaling.
* **Hypothalamic Appetite Regulation:** The structural sequence crosses specialized brain boundaries to interface with pro-opiomelanocortin (POMC) neurons in the arcuate nucleus, signaling a downregulation of food-seeking behaviors and caloric intake pathways.
* **Cardiovascular & Tissue Cytoprotection:** Preclinical data indicates GLP-1 signaling plays an active role in exploring systemic anti-inflammatory pathways, vascular endothelial integrity preservation, and cardiomyocyte stress resistance.

### Research Applications
In preclinical and in vitro laboratory models, Liraglutide vials are actively utilized to investigate:
* High-velocity lipid mobilization, chronic obesity modeling, and adipose tissue browning kinetics.
* Beta-cell proliferation, insulin transcription regulation, and type-2 diabetes cellular pathology.
* Neurological satiety pathway interactions, arcuate nucleus neuroplasticity, and behavioral motivation curves.
* The comparative baseline bioavailability, absorption half-life, and degradation curves of long-acting acylated peptides.

Our Liraglutide vials undergo strict laboratory quality control, stabilization, and vacuum-drying guidelines to ensure absolute ingredient standardization, high chemical purity, and dependable experimental reproducibility.

—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*